Drugs / ALK202
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06707610 | Feb 2025 → Dec 2027 expected | neoplasm | Shanghai Allink Biotherapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07603791 | Jun 2026 → Dec 2027 expected | non-small cell lung carcinoma | Shanghai Allink Biotherapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-09-14 | Shanghai Allink Biotherapeutics Co., Ltd. | Results Allink Biotherapeutics Presents First-in-Human Phase I Data of ALK202, a Potential Best-in-Class EGFR/c-MET Bispecific ADC, at the IASLC 2026 World Conference on Lung Cancer allinkbio.com ↗ |
| 2025-03-14 | Shanghai Allink Biotherapeutics Co., Ltd. | Regulatory EGFR/cMET Bispecific ADC Program - ALK202 Received NMPA IND Approval and Completed First Patient Dosing allinkbio.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-14 | Shanghai Allink Biotherapeutics Co., Ltd. | Allink Biotherapeutics Presents First-in-Human Phase I Data of ALK202, a Potential Best-in-Class EGFR/c-MET Bispecific ADC, at the IASLC 2026 World Conference on Lung Cancer allinkbio.com ↗ |
| 2025-03-14 | Shanghai Allink Biotherapeutics Co., Ltd. | EGFR/cMET Bispecific ADC Program - ALK202 Received NMPA IND Approval and Completed First Patient Dosing allinkbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALK202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07603791 ↗ |
| Route | Intravenous | “Administered intravenously, once every 3 weeks” NCT06707610 ↗ |